U
PTCT icon

UBS’s PTC Therapeutics PTCT Stock Holding History

UBS’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-1,598
Closed -$42K – 10668
2014
Q2 		$42K Buy
+1,598
New +$34.2K ﹤0.01% 7107
2014
Q1 		– Sell
-8,670
Closed -$147K – 10708
2013
Q4 		$147K Buy
8,670
+7,972
+1,142% +$140K ﹤0.01% 5622
2013
Q3 		$15K Buy
+698
New +$12.1K ﹤0.01% 8386

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

UBS's PTCT Position: Q3 2014 in Review

UBS sold out of PTC Therapeutics (PTCT) in Q3 2014, closing a stake of 1,598 shares — an estimated $42K sold.

UBS first reported a position in PTCT in Q3 2013 and held it in 3 quarters. The position peaked at $147K in Q4 2013. 99 funds tracked by Wall St. Rank hold PTCT as of Q3 2014.

  • UBS reported no remaining PTC Therapeutics position as of Q3 2014 after selling out during the quarter.
  • UBS sold 1,598 PTC Therapeutics shares in Q3 2014, an estimated $42K.
  • UBS first reported a position in PTC Therapeutics in Q3 2013 and held it in 3 quarters.
  • UBS's PTC Therapeutics position peaked at $147K in Q4 2013.
  • 99 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.